Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT05614739
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
677 Enrollment(s)
82 Study location(s)
INTERVENTIONAL (PHASE1)
Urinary Bladder Neoplasms
Neoplasm Metastasis
Ureteral Neoplasms
NOT_YET_RECRUITING
NCT07553390
Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers
60 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1)
Breast Cancer
RECRUITING
NCT05945732
DESTINY Breast Respond HER2-(Ultra)Low Europe
2,295 Enrollment(s)
216 Study location(s)
OBSERVATIONAL (None)
Unresectable Breast Cancer


Metastatic Breast Cancer


HER2-low Expressing Breast Cancer


HER2-(Ultra)Low Expressing Breast Cancer
RECRUITING
NCT06846996
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
260 Enrollment(s)
40 Study location(s)
OBSERVATIONAL (None)
HER2-positive Gastric Cancer


HER2-positive Gastroesophageal Junction
RECRUITING
NCT06809764
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
150 Enrollment(s)
36 Study location(s)
OBSERVATIONAL (None)
Non-small Cell Lung Cancer
ACTIVE_NOT_RECRUITING
NCT05246514
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
72 Enrollment(s)
28 Study location(s)
INTERVENTIONAL (PHASE2)
HER2-mutant Non-Small Cell Lung Cancer
RECRUITING
NCT07543536
Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer
132 Enrollment(s)
2 Study location(s)
INTERVENTIONAL (PHASE3)
Advanced/Metastatic Breast Cancer


HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer
ACTIVE_NOT_RECRUITING
NCT05113251
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
927 Enrollment(s)
145 Study location(s)
INTERVENTIONAL (PHASE3)
Breast Neoplasms
Breast Cancer
HER2-positive Early Breast Cancer